The offering is highly dilutive with no minimum, so the actual capital raised is uncertain. Monitor the closing of the offering and subsequent cash burn rate; the company's ability to fund operations beyond the near term depends entirely on this and future capital raises. The ongoing securities class action adds legal overhang.
Executive Summary
BioVie filed Amendment No. 2 to its S-1 registration statement for a best-efforts offering of up to 56.4 million shares of Class A common stock and pre-funded warrants at an assumed price of $1.33 per share. The company, a clinical-stage biopharma with no approved products or revenue, estimates net proceeds of ~$70M for working capital and general corporate purposes, but the offering has no minimum and may raise significantly less. The filing highlights substantial doubt about going concern, an accumulated deficit of ~$368.6M, and ongoing securities class action litigation, making this a highly dilutive capital raise for a cash-burning pre-revenue company.
Key Facts
- BioVie is offering up to 56,390,977 shares of Class A common stock and up to 56,390,977 pre-funded warrants at an assumed price of $1.33 per share.
- The offering is on a best-efforts basis with no minimum offering amount, meaning the company may raise significantly less than the estimated $70.0 million in net proceeds.
- As of March 31, 2026, the company had an accumulated deficit of approximately $368.6 million and cash and cash equivalents of approximately $13.1 million.
- The company has no products approved for commercial sale and has never generated any revenue.
- The company is subject to ongoing securities class action litigation and related shareholder derivative lawsuits.
- The company's auditors have included an explanatory paragraph about substantial doubt concerning its ability to continue as a going concern.
- The company reported a net loss of approximately $5.3 million for the three months ended March 31, 2026, compared to a net loss of approximately $2.8 million for the same period in 2025.
- As of July 28, 2026, there were 7,542,638 shares of common stock outstanding, with additional shares issuable upon exercise of outstanding options (2,785,363) and warrants (8,282,037).
Financial Impact
Estimated net proceeds of ~$70M at the assumed price, but the offering has no minimum and may raise significantly less. The company had $13.1M in cash as of March 31, 2026, and an accumulated deficit of ~$368.6M.
Risk Factors
- The best-efforts offering has no minimum, so the company may raise far less than the estimated $70M.
- The company has no approved products, no revenue, and a history of operating losses, raising substantial doubt about its ability to continue as a going concern.
- Ongoing securities class action and derivative lawsuits could result in significant legal costs and damages.
- The company has a history of dilutive capital raises, and this offering will further dilute existing shareholders.
- The company's stock price is volatile and may decline further due to dilution and operational risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001520138-26-000313 |
| Document: bivi_s1a2ex23z1.htm | 0001520138-26-000313 |
| Document: 0001520138-26-000313-index-headers.html | 0001520138-26-000313 |
| Document: 0001520138-26-000313-index.html | 0001520138-26-000313 |
| Document: 0001520138-26-000313.txt | 0001520138-26-000313 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $1.37 | awaiting T+20 | — | $1.44 (+5.11%) |
Sep 15, 2026 6w ago | Press Release | $1.75 $1.20 | ▼ −31.43% | ▼ −34.41% | $1.44 (−17.71%) |
Aug 14, 2026 10w ago | S-1/A | $1.17 $1.75 | ▼ −49.57% | ▼ −51.55% | $1.44 (−23.08%) |
Aug 6, 2026 11w ago | S-1/A | $1.35 $2.03 | ▼ −50.37% | ▼ −49.77% | $1.44 (−6.67%) |
Aug 6, 2026 11w ago | 8-K | $1.35 $2.03 | ▲ +50.37% | ▲ +49.77% | $1.44 (+6.67%) |
Jul 31, 2026 12w ago | S-1/A | $1.62 $2.28 | ▼ −40.74% | ▼ −39.50% | $1.44 (+11.11%) |
Jun 30, 2026 17w ago | EFFECT | $1.94 $1.37 | ▲ +29.38% | ▲ +28.35% | $1.44 (+25.77%) |
Apr 27, 2026 26w ago | Press Release | $1.59 $1.44 | ▼ −9.43% | ▼ −14.39% | $1.44 (−9.43%) |
Apr 14, 2026 28w ago | Press Release | $1.46 $1.35 | ▼ −7.53% | ▼ −13.83% | $1.44 (−1.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers